Aurinia Pharmaceuticals (AUPH) Finished Goods (2023 - 2026)

Aurinia Pharmaceuticals has reported Finished Goods for 4 years, with the latest figure at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 17.84% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 17.84% YoY), and the FY2025 full-year result was $379000.0, down 58.03% from the prior year.
• Finished Goods for Q1 2026 stood at $4.3 million, up from $379000.0 in the prior quarter.
• The five-year high for Finished Goods was $4.3 million in Q1 2026, with the low at $379000.0 in Q4 2025.
• Historically, Finished Goods has averaged $2.0 million across 4 years, with a median of $1.4 million in 2025.
• Annual changes were most pronounced in 2024 — Finished Goods surged 54.89% — and 2025, when it sank 58.03%.
• Aurinia Pharmaceuticals' Finished Goods stood at $583000.0 in 2023, then surged by 54.89% to $903000.0 in 2024, then slumped by 58.03% to $379000.0 in 2025, then jumped by 1043.54% to $4.3 million in 2026.
• The last three Finished Goods figures came in at $4.3 million (Q1 2026), $379000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.